Glenmark Pharmaceuticals is said to have launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19 at a price of about Rs 103 per tablet.
The drug will be available as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for a strip of 34 tablets, the company spokesperson said.
FabiFlu will be the first oral favipiravir-approved medication in India for the treatment of COVID-19. It is a prescription-based medication, with recommended dose being 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14.
Over 82000 patients are expected to benefit from the new vaccine in the first month itself as the company is looking at offering 2 strips per patient only.
The product is expected to be available at hospitals and retail channel too.